✦ LIBER ✦

Overweight as an adverse prognostic factor for non-Hodgkin’s lymphoma patients receiving high-dose chemotherapy and autograft

✍ Scribed by Tarella, C; Caracciolo, D; Gavarotti, P; Argentino, C; Zallio, F; Corradini, P; Novero, D; Magnani, C; Pileri, A

Book ID: 110012856
Publisher: Nature Publishing Group
Year: 2000
Tongue: English
Weight: 79 KB
Volume: 26
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bmt.1702692

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment outcome and prognostic factors

Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin’s lymphoma

✍ Lee, S M; Ryder, W D J; Clemons, M J; Morgenstern, G R; Chang, J; Scarffe, J H; 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 67 KB

Long-term follow-up of patients receivin

Long-term follow-up of patients receiving salvage chemotherapy for intermediate and high grade non-Hodgkin's lymphomas

✍ Dr. Raymond H. S. Liang; Edmond K. W. Chiu; T. K. Chan; David Todd; Ronald P. Ng 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 423 KB 👁 1 views

This is an analysis of the long-term follow-up data of 99 patients receiving HOAP-Bleo, IMVP-16 and PAC as salvage chemotherapy for refractory or relapsed intermediate or high grade non-Hodgkin's lymphomas. Most of the patients received HOAP-Bleo or PAC following failure of initial chemotherapy and

A prospective study of intensive inducti

A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin’s lymphoma and two or three adverse prognostic factors

✍ Dumontet, C; Thieblemont, C; Espinouse, D; Bouafia, F; Hequet, O; Salles, G; Coi 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 110 KB

Prognostic factors for disease progressi

Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma

✍ Popat, U; Hosing, C; Saliba, R M; Anderlini, P; Besien, K van; Przepiorka, D; Kh 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 167 KB

Concurrent administration of high-dose c

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

✍ Ladetto, M; Zallio, F; Vallet, S; Ricca, I; Cuttica, A; Caracciolo, D; Corradini 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 151 KB

High serum vascular endothelial growth f

High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy

✍ Sari Riihijärvi; Heidi Nurmi; Harald Holte; Magnus Björkholm; Øystein Fluge; Lar 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB